|
[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
|
[2] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med,2019,380(15):1450-1462.
|
|
[3] LONARDO A,BYRNE CD,CALDWELL SH,et al. Global epidemiology of nonalcoholic fatty liver disease:Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology,2016,64(4):1388-1389.
|
|
[4] EL-SERAG HB,HAMPEL H,JAVADI F. The association between diabetes and hepatocellular carcinoma:A systematic review of epidemiologic evidence[J]. Clin Gastroenterol Hepatol,2006,4(3):369-380.
|
|
[5] LOOMBA R,ABRAHAM M,UNALP A,et al. Association between diabetes,family history of diabetes,and risk of nonalcoholic steatohepatitis and fibrosis[J]. Hepatology,2012,56(3):943-951.
|
|
[6] YOUNOSSI ZM. Non-alcoholic fatty liver disease-A global public health perspective[J]. J Hepatol,2019,70(3):531-544.
|
|
[7] YOUNOSSI Z,ANSTEE QM,MARIETTI M,et al. Global burden of NAFLD and NASH:Trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.
|
|
[8] KANWAL F,KRAMER JR,MAPAKSHI S,et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease[J].Gastroenterology,2018,155(6):1828-1837,e1822.
|
|
[9] YOUNOSSI ZM,OTGONSUREN M,HENRY L,et al. Association of nonalcoholic fatty liver disease(NAFLD)with hepatocellular carcinoma(HCC)in the United States from 2004 to2009[J]. Hepatology,2015,62(6):1723-1730.
|
|
[10] YANG JD,LARSON JJ,WATT KD,et al. Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the united states[J]. Clin Gastroenterol Hepatol,2017,15(5):767-775.
|
|
[11] FABBRINI E,MOHAMMED BS,MAGKOS F,et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease[J]. Gastroenterology,2008,134(2):424-431.
|
|
[12] KANDA T,GOTO T,HIROTSU Y,et al. Molecular mechanisms:Connections between nonalcoholic fatty liver disease,steatohepatitis and hepatocellular carcinoma[J]. Int J Mol Sci,2020,21(4):1525.
|
|
[13] BEGRICHE K,MASSART J,ROBIN MA,et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease[J]. Hepatology,2013,58(4):1497-1507.
|
|
[14] TANAKA S,MIYANISHI K,KOBUNE M,et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma[J]. J Gastroenterol,2013,48(11):1249-1258.
|
|
[15] BAFFY G. Hepatocellular carcinoma in obesity:Finding a needle in the haystack?[J]. Adv Exp Med Biol,2018,1061:63-77.
|
|
[16] KIM J,KUNDU M,VIOLLET B,et al. AMPK and m TOR regulate autophagy through direct phosphorylation of Ulk1[J]. Nat Cell Biol,2011,13(2):132-141.
|
|
[17] SINGH SS,VATS S,CHIA AY,et al. Dual role of autophagy in hal marks of cancer[J]. Oncogene,2018,37(9):1142-1158.
|
|
[18] SCHWABE RF,GRETEN TF. Gut microbiome in HCC-Mechanisms,diagnosis and therapy[J]. J Hepatol,2020,72(2):230-238.
|
|
[19] WOLF MJ,ADILI A,PIOTROWITZ K,et al. Metabolic activation of intrahepatic CD8+T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes[J]. Cancer Cell,2014,26(4):549-564.
|
|
[20] MA C,KESARWALA AH,EGGERT T,et al. NAFLD causes selective CD4(+)T lymphocyte loss and promotes hepatocarcinogenesis[J]. Nature,2016,531(7593):253-257.
|
|
[21] TILG H,MOSCHEN AR,RODEN M. NAFLD and diabetes mellitus[J]. Nat Rev Gastroenterol Hepatol,2017,14(1):32-42.
|
|
[22] MARCHESINI G,BRIZI M,MORSELLI-LABATE AM,et al.Association of nonalcoholic fatty liver disease with insulin resistance[J]. Am J Med,1999,107(5):450-455.
|
|
[23] MARCHESINI G,BRIZI M,BIANCHI G,et al. Nonalcoholic fatty liver disease:A feature of the metabolic syndrome[J].Diabetes,2001,50(8):1844-1850.
|
|
[24] KWOK R,CHOI KC,WONG GL,et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:A prospective cohort study[J]. Gut,2016,65(8):1359-1368.
|
|
[25] KOEHLER EM,PLOMPEN EP,SCHOUTEN JN,et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population:The Rotterdam study[J].Hepatology,2016,63(1):138-147.
|
|
[26] DOYCHEVA I,CUI J,NGUYEN P,et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE[J]. Aliment Pharmacol Ther,2016,43(1):83-95.
|
|
[27] ALEXANDER M,LOOMIS AK,van der LEI J,et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD:Real-world study of 18 million patients in four European cohorts[J]. BMC Med,2019,17(1):95.
|
|
[28] HOSSAIN N,AFENDY A,STEPANOVA M,et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2009,7(11):1224-1229.
|
|
[29] TALIM M. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients:Response to Targher et al. and Hu et al[J]. Diabetes Care,2007,30(6):e55; author reply e56.
|
|
[30] TARGHER G,BERTOLINI L,RODELLA S,et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients[J].Diabetologia,2008,51(3):444-450.
|
|
[31] MALAGUARNERA R,BELFIORE A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells[J]. Front Endocrinol(Lausanne),2014,5:10.
|
|
[32] GEHMERT S,SADAT S,SONG YH,et al. The anti-apoptotic effect of IGF-1 on tissue resident stem cells is mediated via PI3-kinase dependent secreted frizzled related protein 2(Sfrp2)release[J]. Biochem Biophys Res Commun,2008,371(4):752-755.
|
|
[33] LI ZY,YANG Y,MING M,et al. Mitochondrial ROS generation for regulation of autophagic pathways in cancer[J]. Biochem Biophys Res Commun,2011,414(1):5-8.
|
|
[34] AHMAD S,KHAN H,SIDDIQUI Z,et al. AGEs,RAGEs and s-RAGE; friend or foe for cancer[J]. Semin Cancer Biol,2018,49:44-55.
|
|
[35] BERROU J,FOUGERAY S,VENOT M,et al. Natural killer cell function,an important target for infection and tumor protection,is impaired in type 2 diabetes[J]. PLo S One,2013,8(4):e62418.
|
|
[36] FRYDRYCH LM,BIAN G,O’LONE DE,et al. Obesity and type 2 diabetes mellitus drive immune dysfunction,infection development,and sepsis mortality[J]. J Leukoc Biol,2018,104(3):525-534.
|
|
[37] DYSON J,JAQUES B,CHATTOPADYHAY D,et al. Hepatocellular cancer:The impact of obesity,type 2 diabetes and a multidisciplinary team[J]. J Hepatol,2014,60(1):110-117.
|
|
[38] YASUI K,HASHIMOTO E,KOMORIZONO Y,et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol,2011,9(5):428-433; quiz e50.
|
|
[39] MAKAROVA-RUSHER OV,ALTEKRUSE SF,MCNEEL TS,et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States[J]. Cancer,2016,122(11):1757-1765.
|
|
[40] YANG JD,AHMED F,MARA KC,et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease[J]. Hepatology,2020,71(3):907-916.
|
|
[41] KANWAL F,KRAMER JR,LI L,et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease[J]. Hepatology,2020,71(3):808-819.
|
|
[42] IOANNOU GN,GREEN P,LOWY E,et al. Differences in hepatocellular carcinoma risk,predictors and trends over time according to etiology of cirrhosis[J]. PLo S One,2018,13(9):e0204412.
|
|
[43] ALEKSANDROVA K,BOEING H,NTHLINGS U,et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer[J]. Hepatology,2014,60(3):858-871.
|
|
[44] ASCHA MS,HANOUNEH IA,LOPEZ R,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J]. Hepatology,2010,51(6):1972-1978.
|
|
[45] WANG P,KANG D,CAO W,et al. Diabetes mel itus and risk of hepatocellular carcinoma:A systematic review and meta-analysis[J]. Diabetes Metab Res Rev,2012,28(2):109-122.
|
DownLoad: